Rhelion Life Sciences Corp.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| 4YX0.F | 31R.F | RDHL | RUA.NZ | LABS.TO | IXHL | |
|---|---|---|---|---|---|---|
| Market cap | 1.23M | 2.18M | 3.76M | 9.14M | 27.77M | 33.12M |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | — | — | 14.1 | — | -6.5 | -1.5 |
| Price/book | 0.1 | -0.9 | 0.5 | 2.0 | 0.8 | 0.5 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −77.60% | +650.00% | −74.27% | −31.58% | −13.33% | −75.17% |
| Today | −64.29% | −33.33% | +0.26% | 0.00% | 0.00% | +1.54% |
The closest companies by business and industry (Drug Manufacturers - Specialty & Generic). Prices may be delayed up to 15 min.
Latest news
All 4YX0.F news ›Rhelion Life Sciences Corp. Stock (RHEL) - Quote Canadian Securities Exchange
Rhelion Life Sciences Corp., formerly Red Light Holland Corp., is a science and research led company advancing the natural psychedelic drug discovery and development sector. Through its wholly owned subsidiary Filament Health Corp., the…
Rhelion Life Sciences Corp.: Relative Strength Chart - Stock Canadian Securities Exchange
Compare Rhelion Life Sciences Corp. with the company of your choice via a Relative Strength chart. Real-time RHEL price, Canadian Securities Exchange stock exchange Relative Strength Chart Rhelion Life Sciences Corp. All financial news and…
Rhelion Life Sciences Unit Expands Supply Agreement with University of Chieti-Pescara for PEX010
Rhelion Life Sciences' Filament Health unit expanded its supply and license agreement with the University G. d'Annunzio of Chieti-Pescara for the supply of PEX010, its psilocybin drug candidate,... Rhelion Life Sciences Corp. Rhelion Life…
Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health to Supply Belgium's First Psilocybin Compassionate Use Program, to Help Open the Door to Patient Access for Treatment-Resistant Depression
Published on 10/16/2026 at 08:56 am EDT The program is led by Dr. Daniel Souery at Epsylon. Epsylon is the applicant for the program. Filament is not responsible for the conduct of the program. "Access to psilocybin treatment is growing…
Rhelion Life Sciences Reappoints Dr. Robin Carhart-Harris as Scientific Advisor
The proposed share-based settlement would extinguish approximately $100,000 of debt, subject to final exchange approval. Rhelion Life Sciences (TRUFF) has signed a new agreement reappointing Dr. Robin Carhart-Harris as scientific advisor…
Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Signs Licence Agreement with the University of California, San Francisco for a Phase 2 Trial of Psilocybin in Methamphetamine Use Disorder Among People with HIV
Filament will provide trial capsules and regulatory documentation, including authorization to reference its drug master files. Rhelion Life Sciences (TRUFF) subsidiary Filament Health signed a licence and supply agreement with UCSF for a…
From articles in the 4Search news index.